Per citar aquest document: http://ddd.uab.cat/record/143104
Interruptions of antiretroviral therapy in human immunodeficiency virus infection : are they detrimental to neurocognitive functioning?
Muñoz-Moreno, Jose Antonio (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida)
Fumaz, Carmina R. (Rodríguez Fumaz) (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida)
Prats, Anna (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida)
Ferrer, Maria J. (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida)
Negredo Puigmal, Eugènia (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida)
Pérez-Álvarez, Núria (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida)
Moltó, José (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida)
Gómez Melis, Guadalupe (Universitat Politècnica de Catalunya)
Garolera i Freixa, Maite (Consorci Sanitari Hospital de Terrassa)
Clotet Sala, Bonaventura (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida)
Universitat Autònoma de Barcelona

Data: 2010
Resum: Background: Since interruptions of antiretroviral treatment may entail clinical risks for HIV-infected individuals, we investigated their impact on neurocognitive functioning. Methods: Cross-sectional study comparing HIV-infected persons who had interrupted antiretroviral therapy in the past (interruption group, IG) with persons who had never discontinued therapy (non-interruption group, NIG). Interruption was defined as the discontinuation of HAART for more than 15 days after previous treatment of at least 15 days. All the participants were on therapy. Demographic, clinical, and neurocognitive variables were assessed. The primary end point was the percentage of people with neurocognitive impairment. The score in different neurocognitive domains was a secondary end point. Results: A total of 83 subjects participated in the study (IG: n=27, NIG: n=56). Demographic and clinical characteristics were balanced between the groups, except for years since HIV diagnosis (IG, 13. 8; NIG, 10. 2 [p=0. 003]). The percentage of people with neurocognitive impairment was significantly higher in the IG group (IG, 59. 25%; NIG, 33. 92% [p=0. 02]). As for scores in neurocognitive domains, individuals in the IG showed worse neurocognitive functioning, and significant differences in attention/working memory and information processing speed were found. The adjusted analysis supported the unadjusted analysis. Conclusions: In our study, a higher prevalence of neurocognitive impairment was detected in HIV-infected persons who had interrupted antiretroviral therapy in the past. Additionally, neurocognitive functioning was observed to be more impaired in the same individuals. Further studies should examine the potential negative effects of antiretroviral therapy interruptions on neurocognitive functioning.
Nota: Número d'acord de subvenció FIPSE/2355/02
Nota: Número d'acord de subvenció MICINN/MTM2008-06747-C02-00
Nota: Número d'acord de subvenció ISCIII/RETICS/RD06/0006
Drets: Tots els drets reservats
Llengua: Anglès
Document: article ; recerca ; acceptedVersion
Matèria: antiretroviral therapy ; HIV infection ; neurocognitive functioning ; neuropsychological assessment ; treatment interruption
Publicat a: Journal of Neurovirology, Vol. 16, Issue 3 (May 2010) , p. 208-218, ISSN 1355-0284

DOI: 10.3109/135502810037677


Post-print
19 p, 76.2 KB

Figura 1
1 p, 11.3 KB

Figura 2
1 p, 137.1 KB

Taula 1
1 p, 14.4 KB

Taula 2
1 p, 59.2 KB

Taula 3
1 p, 15.6 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats

 Registre creat el 2015-11-11, darrera modificació el 2016-06-04



   Favorit i Compartir